nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - sieri immuni e immunoglobuline, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.
ig vaiolo
sclavo s.p.a. - immunoglobuline specifiche - immunoglobuline specifiche
morbulin
immuno s.r.l. - immunoglobuline specifiche - immunoglobuline specifiche
gamma men
nuovo istituto sieroterapico milanese s.r.l. - immunoglobuline specifiche - immunoglobuline specifiche
rubellabulin
immuno s.r.l. - immunoglobuline specifiche - immunoglobuline specifiche
pressimmun
istituto behring spa - immunoglobuline specifiche - immunoglobuline specifiche
venogamma anti rho (d)
alfa wassermann s.p.a. - immunoglobuline specifiche - immunoglobuline specifiche
gammagard
baxter s.p.a. - immunoglobuline specifiche - immunoglobuline specifiche
lymphoser
crucell italy s.r.l. - immunoglobuline specifiche - immunoglobuline specifiche
intrazig
istituto sierovaccinogeno italiano i.s.i. s.p.a. - immunoglobuline specifiche - immunoglobuline specifiche